This increased production capacity translates into a total of 10,000 courses of Ropren(R) per month, or 120,000 courses per year.
The Board is also pleased to report that Dr Victoria Gorbacheva has now joined Solagran as General Manager, Solagran Russia. Dr Gorbacheva has brought with her a five person team with which to manage the marketing of Ropren(R) in St Petersburg and Moscow.
At this stage, there are nine hospitals across these two cities that are waiting to receive their initial supply of Ropren(R). Firm orders will be confirmed when pricing has been finalised and will be announced to the market at that time. Marketing to senior clinicians outside these nine institutions will also commence at that time.
This increased production capacity translates into a total of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.25M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.0¢ | 17.5¢ | $10.73K | 59.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 12933 | 1 |
View Market Depth
| Last trade - 15.05pm 17/09/2025 (20 minute delay) ? |
| SLA (ASX) Chart |